Cover Image
市場調查報告書

社區型肺炎:開發平台分析

Community Acquired Pneumonia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257817
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
Back to Top
社區型肺炎:開發平台分析 Community Acquired Pneumonia - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 111 Pages
簡介

本報告提供社區型肺炎的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等,為您概述為以下內容。

目錄

簡介

社區型肺炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Allergan Plc
  • AstraZeneca Plc
  • Biotest AG
  • C10 Pharma AS
  • kyorin製藥
  • Paratek Pharmaceuticals, Inc.
  • TaiGen Biotechnology Co., Ltd.
  • 武田藥品工業

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BT-086
  • C-10
  • ceftaroline fosamil
  • dalbavancin
  • KRPAM-1977X
  • nemonoxacin
  • omadacycline tosylate
  • ticagrelor

最新開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8274IDB

Summary

Global Markets Direct's, 'Community Acquired Pneumonia - Pipeline Review, H2 2016', provides an overview of the Community Acquired Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia
  • The report reviews pipeline therapeutics for Community Acquired Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Community Acquired Pneumonia therapeutics and enlists all their major and minor projects
  • The report assesses Community Acquired Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Community Acquired Pneumonia Overview
  • Therapeutics Development
    • Pipeline Products for Community Acquired Pneumonia - Overview
  • Community Acquired Pneumonia - Therapeutics under Development by Companies
  • Community Acquired Pneumonia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Community Acquired Pneumonia - Products under Development by Companies
  • Community Acquired Pneumonia - Companies Involved in Therapeutics Development
    • Aridis Pharmaceuticals LLC
    • BioAegis Therapeutics, Inc.
    • Biotest AG
    • C10 Pharma AS
    • InflaRx GmbH
    • ioGenetics, Inc.
    • Kyorin Pharmaceutical Co., Ltd.
    • Lascco SA
    • Melinta Therapeutics, Inc
    • Merck & Co., Inc.
    • Nabriva Therapeutics AG
    • Paratek Pharmaceuticals, Inc.
    • TaiGen Biotechnology Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • Tetraphase Pharmaceuticals Inc.
    • TiGenix NV
  • Community Acquired Pneumonia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BT-086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAL-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ceftaroline fosamil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cx-611 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DBAF-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IFX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KRPAM-1977X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KRPAM-1977Y - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lefamulin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nemonoxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omadacycline tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PneumoMab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • radezolid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tosatoxumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Community Acquired Pneumonia - Dormant Projects
  • Community Acquired Pneumonia - Discontinued Products
  • Community Acquired Pneumonia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 28, 2016: Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
      • Jun 20, 2016: Nabriva Presents Data on Lefamulin at the American Society of Microbiology Microbe 2016 Conference
      • Jun 16, 2016: Cempra to Host Analyst and Investor Day on June 23, 2016
      • Jun 14, 2016: Melinta Therapeutics Presenting Results From Baxdela Programs At ASM Microbe 2016 Meeting
      • Jun 13, 2016: TaiGen Biotechnology Receives Market Approval from the China Food and Drug Administration for Taigexyn (nemonoxacin)
      • Jun 10, 2016: Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference
      • May 31, 2016: Allergan Receives FDA Approval of TEFLARO (ceftaroline fosamil) for Pediatric Patients
      • May 25, 2016: Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)
      • May 16, 2016: Nabriva Announces Lefamulin Presentation at ASM Microbe 2016 Conference
      • May 12, 2016: Cempra to Present Solithromycin IV Data at ATS 2016
      • May 01, 2016: Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
      • Apr 11, 2016: Nabriva Initiates Second Phase 3 Clinical Trial of Lefamulin ("LEAP 2") in Patients with Community-Acquired Bacterial Pneumonia
      • Apr 04, 2016: Cempra to Present Data on Solithromycin at ECCMID
      • Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets
      • Feb 05, 2016: The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra Oral Solithromycin in Community-Acquired Bacterial Pneumonia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Community Acquired Pneumonia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Community Acquired Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Community Acquired Pneumonia - Pipeline by BioAegis Therapeutics, Inc., H2 2016
  • Community Acquired Pneumonia - Pipeline by Biotest AG, H2 2016
  • Community Acquired Pneumonia - Pipeline by C10 Pharma AS, H2 2016
  • Community Acquired Pneumonia - Pipeline by InflaRx GmbH, H2 2016
  • Community Acquired Pneumonia - Pipeline by ioGenetics, Inc., H2 2016
  • Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Community Acquired Pneumonia - Pipeline by Lascco SA, H2 2016
  • Community Acquired Pneumonia - Pipeline by Melinta Therapeutics, Inc, H2 2016
  • Community Acquired Pneumonia - Pipeline by Merck & Co., Inc., H2 2016
  • Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG, H2 2016
  • Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016
  • Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016
  • Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016
  • Community Acquired Pneumonia - Pipeline by TiGenix NV, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Community Acquired Pneumonia - Dormant Projects, H2 2016
  • Community Acquired Pneumonia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Community Acquired Pneumonia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top